Wang Y, Qin J, Sharma A, Dakal T, Wang J, Pan T
Cancer Cell Int. 2024; 24(1):305.
PMID: 39227952
PMC: 11373255.
DOI: 10.1186/s12935-024-03487-y.
Kozalak G, Kosar A
Cancer Drug Resist. 2024; 6:838-857.
PMID: 38239705
PMC: 10792488.
DOI: 10.20517/cdr.2023.108.
Leeksma A, Derks I, Garrick B, Jongejan A, Colombo M, Bloedjes T
Mol Oncol. 2022; 17(2):284-297.
PMID: 36400430
PMC: 9892823.
DOI: 10.1002/1878-0261.13343.
Bloedjes T, de Wilde G, Khan G, Ashby T, Shaughnessy J, Zhan F
Blood Adv. 2022; 7(9):1697-1712.
PMID: 36322819
PMC: 10182179.
DOI: 10.1182/bloodadvances.2022007383.
John L, Krauth M, Podar K, Raab M
Cancers (Basel). 2021; 13(7).
PMID: 33916289
PMC: 8036678.
DOI: 10.3390/cancers13071668.
Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W, Fu Y, Zheng Y, Wang X, Liu B, Zeng J
BMC Cancer. 2021; 21(1):125.
PMID: 33549034
PMC: 7866463.
DOI: 10.1186/s12885-021-07833-5.
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.
Bloedjes T, de Wilde G, Guikema J
Cancers (Basel). 2021; 13(3).
PMID: 33494394
PMC: 7865460.
DOI: 10.3390/cancers13030396.
AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.
Bloedjes T, de Wilde G, Maas C, Eldering E, Bende R, van Noesel C
Blood Adv. 2020; 4(17):4151-4164.
PMID: 32898245
PMC: 7479958.
DOI: 10.1182/bloodadvances.2019001393.
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.
Wen Z, Rajagopalan A, Flietner E, Yun G, Chesi M, Furumo Q
Blood. 2020; 137(1):61-74.
PMID: 32640012
PMC: 7808014.
DOI: 10.1182/blood.2020007156.
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.
Lucas C, Scott L, Carmell N, Holcroft A, Hills R, Burnett A
Blood Adv. 2018; 2(9):964-968.
PMID: 29703716
PMC: 5941996.
DOI: 10.1182/bloodadvances.2017013615.
Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation.
Huang H, Lin X, Lin Y, Yao R, He M
Indian J Hematol Blood Transfus. 2018; 34(2):268-272.
PMID: 29622868
PMC: 5884994.
DOI: 10.1007/s12288-017-0883-z.
Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L
Haematologica. 2018; 103(4):707-716.
PMID: 29326121
PMC: 5865414.
DOI: 10.3324/haematol.2017.167486.
Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.
Liu X, Cao W, Qin S, Zhang T, Zheng J, Dong Y
Signal Transduct Target Ther. 2017; 2:17013.
PMID: 29263916
PMC: 5661621.
DOI: 10.1038/sigtrans.2017.13.
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
Templin J, Atanackovic D, Hasche D, Radhakrishnan S, Luetkens T
Oncotarget. 2017; 8(30):49253-49263.
PMID: 28512269
PMC: 5564765.
DOI: 10.18632/oncotarget.17534.
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang R, Wang Y, Zhang N, Xu W, Cao Y, Tong J
Cell Death Dis. 2017; 8(5):e2776.
PMID: 28492559
PMC: 5520709.
DOI: 10.1038/cddis.2017.188.
PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C, Huang X, Liu H, Xiao F, Wei J, You L
Oncotarget. 2017; 8(24):39185-39197.
PMID: 28402933
PMC: 5503605.
DOI: 10.18632/oncotarget.16642.
Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.
Ding J, Yuan L, Chen G
Oncol Lett. 2017; 13(2):647-654.
PMID: 28356941
PMC: 5351279.
DOI: 10.3892/ol.2016.5472.
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock R, Loughran N, Marlein C, Robinson S, Edwards D, Yu S
Blood Cancer J. 2017; 7(3):e539.
PMID: 28282033
PMC: 5380901.
DOI: 10.1038/bcj.2017.16.
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S, Carrino M, Manzoni M, Gianesin K, Canovas Nunes S, Costacurta M
Oncotarget. 2017; 8(9):14604-14619.
PMID: 28099937
PMC: 5362429.
DOI: 10.18632/oncotarget.14654.
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
Keppler S, WeiBbach S, Langer C, Knop S, Pischimarov J, Kull M
Oncotarget. 2016; 7(25):38762-38774.
PMID: 27246973
PMC: 5122427.
DOI: 10.18632/oncotarget.9607.